

Shreyaskumar R Patel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2406989/publications.pdf>

Version: 2024-02-01

134
papers

11,406
citations

71061

41
h-index

30058

103
g-index

139
all docs

139
docs citations

139
times ranked

10299
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 3383-3391.	2.0	9
2	Computational Drug Repositioning Identifies Potentially Active Therapies for Chordoma. <i>Neurosurgery</i> , 2021, 88, 428-436.	0.6	7
3	Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. <i>Cancer</i> , 2021, 127, 1311-1317.	2.0	8
4	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskkeletal Ewing Sarcoma. <i>Oncologist</i> , 2021, 26, 250-260.	1.9	9
5	Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 871-882.	1.1	12
6	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	2.0	96
7	A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3037-3049.	1.0	2
8	An updated review of the treatment landscape for advanced gastrointestinal stromal tumors. <i>Cancer</i> , 2021, 127, 2187-2195.	2.0	16
9	Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 3565-3574.	1.3	6
10	Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, , .	0.7	5
11	Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3128-3139.	0.8	56
12	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	1.9	6
13	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. <i>Sarcoma</i> , 2020, 2020, 1-6.	0.7	16
14	Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. <i>Cancers</i> , 2020, 12, 2927.	1.7	12
15	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1165-1172.	1.9	15
16	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020, 12, 1768.	1.7	20
17	Molecular Imaging with ^{18}F -deoxy- ^{18}F -Fluorothymidine (^{18}F -FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. <i>Diagnostics</i> , 2020, 10, 125.	1.3	5
18	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , 2020, 11, 1008.	5.8	143

#	ARTICLE	IF	CITATIONS
19	Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma. <i>Oncologist</i> , 2019, 24, 110-116.	1.9	34
20	Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. <i>Cancer</i> , 2019, 125, 4435-4441.	2.0	10
21	Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. <i>Cancer</i> , 2019, 125, 2610-2620.	2.0	47
22	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , 2019, 11, 677.	1.7	20
23	Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment. <i>Current Oncology Reports</i> , 2018, 20, 13.	1.8	71
24	The challenge of the management of adolescents and young adults with soft tissue sarcomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27013.	0.8	24
25	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. <i>Oncologist</i> , 2018, 23, 360-366.	1.9	36
26	Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. <i>JAMA Oncology</i> , 2018, 4, 814.	3.4	26
27	Ewing Sarcoma of the Spine. <i>Spine</i> , 2018, 43, 622-629.	1.0	27
28	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018, 23, 62-70.	1.9	62
29	SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. <i>Sarcoma</i> , 2018, 2018, 1-9.	0.7	13
30	Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. <i>BMC Cancer</i> , 2018, 18, 913.	1.1	69
31	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4865-4873.	3.2	68
32	Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10520-10520.	0.8	0
33	Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11522-11522.	0.8	0
34	Whole exome sequencing (WES) of metastatic leiomyosarcoma (LMS) and liposarcoma (LPS) and correlation of genomic aberrations with clinical outcomes in the phase III randomized trial of trabectedin (T) vs. dacarbazine (D).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11513-11513.	0.8	0
35	Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 34.	1.3	13
36	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1493-1501.	5.1	921

#	ARTICLE	IF	CITATIONS
37	The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. <i>Current Oncology Reports</i> , 2017, 19, 78.	1.8	32
38	Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. <i>Scientific Reports</i> , 2017, 7, 9519.	1.6	15
39	Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1335.e13-1335.e15.	0.8	46
40	Clinical trial enrollment of adolescents and young adults with sarcoma. <i>Cancer</i> , 2017, 123, 3434-3440.	2.0	29
41	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. <i>Oncologist</i> , 2017, 22, 1271-1277.	1.9	20
42	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017, 7, 15963.	1.6	21
43	The role of revision surgery and adjuvant therapy following subtotal resection of osteosarcoma of the spine: a systematic review with meta-analysis. <i>Journal of Neurosurgery: Spine</i> , 2017, 27, 97-104.	0.9	27
44	Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. <i>Gynecologic Oncology</i> , 2017, 146, 531-537.	0.6	51
45	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. <i>Clinical Sarcoma Research</i> , 2017, 7, 11.	2.3	61
46	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. , 2017, 5, 100.		114
47	Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion. <i>Sarcoma</i> , 2017, 2017, 1-6.	0.7	3
48	Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11008-11008.	0.8	32
49	Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028.. <i>Journal of Clinical Oncology</i> , 2017, 35, 60-60.	0.8	3
50	Increase in the patient wait-time and delays in the clinic workflow post-implementation of the electronic health record.. <i>Journal of Clinical Oncology</i> , 2017, 35, 194-194.	0.8	0
51	Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11019-11019.	0.8	0
52	Impact of room pooling and electronic health record on patient (pt) wait time, clinic work flow, and ptsâ€™/providersâ€™ satisfaction.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18191-e18191.	0.8	0
53	SARC009: Phase 2 study of dasatinib in patients with previously treated, highâ€grade, advanced sarcoma. <i>Cancer</i> , 2016, 122, 868-874.	2.0	80
54	An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. <i>Current Oncology Reports</i> , 2016, 18, 49.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports, 2016, 6, 35448.	1.6	12
56	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Medicine, 2016, 5, 3437-3444.	1.3	20
57	Clinical Decision Making. Spine, 2016, 41, S171-S177.	1.0	7
58	A Systematic Review of Clinical Outcomes and Prognostic Factors for Patients Undergoing Surgery for Spinal Metastases Secondary to Breast Cancer. Global Spine Journal, 2016, 6, 482-496.	1.2	39
59	Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. Journal of Clinical Oncology, 2016, 34, 3680-3685.	0.8	17
60	Chemotherapy for soft tissue sarcoma. Cancer, 2016, 122, 2952-2960.	2.0	148
61	Predictors of survival in patients with sarcoma admitted to the intensive care unit. Clinical Sarcoma Research, 2016, 6, 12.	2.3	4
62	Can Abdominal Computed Tomography Imaging Help Accurately Identify a Dedifferentiated Component in a Well-Differentiated Liposarcoma?. Journal of Computer Assisted Tomography, 2016, 40, 872-879.	0.5	15
63	Chemotherapy for Bone Sarcoma in Adults. Journal of Oncology Practice, 2016, 12, 208-216.	2.5	44
64	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2016, 387, 1629-1637.	6.3	610
65	Assessing the role of 18F-FDG PET and 18F-FDG PET/CT in the diagnosis of soft tissue musculoskeletal malignancies: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 860-870.	3.3	38
66	Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology, 2016, 34, 786-793.	0.8	647
67	Benign Tumors of the Spine. Spine, 2016, 41, S178-S185.	1.0	30
68	Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028â€”A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 11006-11006.	0.8	37
69	Cardiac safety analysis of trabectedin (T) vs. dacarbazine (D) in patients (Pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS) after prior anthracycline chemotherapy.. Journal of Clinical Oncology, 2016, 34, 11060-11060.	0.8	1
70	Patient-reported outcomes from randomized, phase-3 study of trabectedin (T) vs. dacarbazine (D) in advanced leiomyosarcoma (LMS) or liposarcoma (LPS).. Journal of Clinical Oncology, 2016, 34, 11061-11061.	0.8	5
71	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget, 2016, 7, 64421-64430.	0.8	17
72	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	0.8	44

#	ARTICLE	IF	CITATIONS
73	Clinical characteristics of adult alveolar rhabdomyosarcoma (ARMS) patients (Pts) on front-line therapies: An MD Anderson Cancer Center (MDACC) series.. Journal of Clinical Oncology, 2016, 34, 11069-11069.	0.8	0
74	Clinical next-generation sequencing in sarcomas.. Journal of Clinical Oncology, 2016, 34, 11046-11046.	0.8	0
75	Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma. Clinical Sarcoma Research, 2015, 5, 22.	2.3	33
76	STUMP unâ€œstumpedâ€œ anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. Journal of Hematology and Oncology, 2015, 8, 66.	6.9	75
77	Phase 1 adaptive doseâ€œfinding study of neoadjuvant gemcitabine combined with radiation therapy for patients with highâ€œrisk extremity and trunk soft tissue sarcoma. Cancer, 2015, 121, 3659-3667.	2.0	17
78	Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e656-e660.	1.8	13
79	Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?. Clinical Orthopaedics and Related Research, 2015, 473, 3604-3611.	0.7	27
80	Fifty Years of Advances in Sarcoma Treatment: Moving the Needle from Conventional Chemotherapy to Targeted Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 259-262.	1.8	4
81	Adult versus Pediatric Neuroblastoma: The M.D. Anderson Cancer Center Experience. Sarcoma, 2014, 2014, 1-6.	0.7	27
82	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. Clinical Cancer Research, 2014, 20, 4200-4209.	3.2	127
83	THERAPY OF ENDOCRINE DISEASE: Treatment of malignant pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2014, 171, R111-R122.	1.9	91
84	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. European Journal of Cancer, 2014, 50, 1137-1147.	1.3	104
85	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 2014, 32, 1563-1570.	0.8	252
86	Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemotherapy and Pharmacology, 2013, 72, 277-286.	1.1	37
87	Exploring Novel Therapeutic Targets in GIST: Focus on the PI3K/Akt/mTOR Pathway. Current Oncology Reports, 2013, 15, 386-395.	1.8	54
88	Managing progressive disease in patients with GIST: Factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treatment Reviews, 2012, 38, 467-472.	3.4	17
89	Primary Retroperitoneal Tumors. , 2012, , 403-421.		0
90	Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist, 2012, 17, 321-e329.	1.9	100

#	ARTICLE	IF	CITATIONS
91	Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extraadrenal paragangliomas. <i>Cancer</i> , 2012, 118, 2804-2812.	2.0	128
92	Exploiting antitumor immunity to overcome relapse and improve remission duration. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1113-1124.	2.0	39
93	Interleukin-6, Hepcidin, and Other Biomarkers in Anemia of Chronic Disease (ACD) and Chemotherapy-Induced Anemia (CIA): Potential Therapeutic Targets.. <i>Blood</i> , 2012, 120, 2086-2086.	0.6	5
94	Navigating Risk Stratification Systems for the Management of Patients With GIST. <i>Annals of Surgical Oncology</i> , 2011, 18, 1698-1704.	0.7	23
95	Preface. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1-1.	1.1	0
96	Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. <i>Cancer</i> , 2011, 117, 4939-4947.	2.0	212
97	Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 717-725.	1.8	336
98	Should Patients with High-Risk Soft Tissue Sarcoma Receive Adjuvant Chemotherapy?. <i>Oncologist</i> , 2009, 14, 1003-1012.	1.9	40
99	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2009, 373, 1097-1104.	6.3	1,233
100	Pediatric and Adult Osteosarcoma: Comparisons and Contrasts in Presentation and Therapy. <i>Cancer Treatment and Research</i> , 2009, 152, 355-363.	0.2	22
101	Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: Lessons from the phase 3 trials. <i>European Journal of Cancer</i> , 2008, 44, 501-509.	1.3	44
102	Potential Combination Chemotherapy Approaches for Advanced Adult-Type Soft-Tissue Sarcoma. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 207-217.	3.3	20
103	Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria. <i>Journal of Clinical Oncology</i> , 2007, 25, 1753-1759.	0.8	1,354
104	Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002. <i>Journal of Clinical Oncology</i> , 2007, 25, 2755-2763.	0.8	655
105	Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib. <i>Annals of Surgical Oncology</i> , 2006, 14, 14-24.	0.7	220
106	Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. <i>Cancer</i> , 2006, 107, 2237-2244.	2.0	29
107	Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. <i>Cancer</i> , 2006, 107, 2881-2887.	2.0	60
108	Effects of Darbepoetin Alfa Administered Once Per Cycle for the Prevention of Anemia on the Incidence of Transfusions, Neurocognitive Functions, and Symptom Assessment.. <i>Blood</i> , 2006, 108, 4232-4232.	0.6	10

#	ARTICLE	IF	CITATIONS
109	Recent Studies in Novel Therapy for Metastatic Sarcomas. Hematology/Oncology Clinics of North America, 2005, 19, 573-590.	0.9	5
110	Recent Developments in Salvage Chemotherapy for Patients with Metastatic Soft Tissue Sarcoma. Drugs, 2005, 65, 167-178.	4.9	31
111	A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors. Cancer Research, 2004, 64, 5913-5919.	0.4	334
112	A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. Cancer, 2004, 101, 156-163.	2.0	27
113	Advances in neoadjuvant chemotherapy in soft tissue sarcomas. Current Treatment Options in Oncology, 2003, 4, 433-439.	1.3	11
114	Results of a 2-arm Phase II study of 9-nitrocarnitine in patients with advanced soft-tissue sarcomas. Cancer, 2003, 97, 2848-2852.	2.0	31
115	A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer, 2003, 98, 2693-2699.	2.0	116
116	Recent advances in systemic therapy of soft tissue sarcomas. Expert Review of Anticancer Therapy, 2003, 3, 179-184.	1.1	6
117	Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas. Expert Opinion on Investigational Drugs, 2002, 11, 1789-1793.	1.9	1
118	Systemic therapy for advanced soft-tissue sarcomas. Current Oncology Reports, 2002, 4, 299-304.	1.8	6
119	Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate Accumulation. Journal of Clinical Oncology, 2001, 19, 3483-3489.	0.8	234
120	Pilot study of vitaxin?an angiogenesis inhibitor?in patients with advanced leiomyosarcomas. Cancer, 2001, 92, 1347-1348.	2.0	91
121	Management of peritoneal and hepatic metastases from gastrointestinal stromal tumors. Surgical Oncology, 2000, 9, 67-70.	0.8	21
122	Radiation-induced sarcoma. Current Treatment Options in Oncology, 2000, 1, 258-261.	1.3	92
123	Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity in Soft Tissue Sarcomas. Journal of Clinical Oncology, 2000, 18, 3378-3383.	0.8	84
124	New agents in the treatment of soft-tissue sarcomas. Expert Opinion on Investigational Drugs, 2000, 9, 1545-1551.	1.9	7
125	New chemotherapeutic strategies for soft tissue sarcomas. , 1999, 17, 47-51.		14
126	Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas. Investigational New Drugs, 1998, 16, 87-92.	1.2	12

#	ARTICLE	IF	CITATIONS
127	Results of Two Consecutive Trials of Dose-Intensive Chemotherapy With Doxorubicin and Ifosfamide in Patients With Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 317-321.	0.6	187
128	Phase II Study of Paclitaxel in Patients With Soft Tissue Sarcomas. Sarcoma, 1997, 1, 95-97.	0.7	21
129	Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. , 1996, 78, 741-744.		37
130	A 15-year experience with chemotherapy of patients with paraganglioma. Cancer, 1995, 76, 1476-1480.	2.0	93
131	Primary Extraskeletal Osteosarcoma--Experience With Chemotherapy. Journal of the National Cancer Institute, 1995, 87, 1331-1333.	3.0	33
132	Myxoid liposarcoma. Experience with chemotherapy. Cancer, 1994, 74, 1265-1269.	2.0	97
133	Myxoid liposarcoma. Experience with chemotherapy. , 1994, 74, 1265.		4
134	Combination chemotherapy in adult desmoid tumors. Cancer, 1993, 72, 3244-3247.	2.0	225